Short answer
ACCENDRA HEALTH INC/VA/ (ACH) filed its Q3 2025 10-Q quarterly report on Oct 31, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $697M (down 74.4% year over year) with net income of −$150M.
Q3 2025 key financials · XBRL
- Revenue
- $697M
- −74.4% YoY
- Net income
- −$150M
- −1076.7% YoY · +82.7% QoQ
- Operating margin
- 3.8%
- EPS (diluted)
- −$1.95
- −1047.1% YoY · +82.7% QoQ
Source: XBRL data from the ACCENDRA HEALTH INC/VA/ (ACH) Q3 2025 10-Q on SEC EDGAR. USD.
ACCENDRA HEALTH INC/VA/ Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $697.3M, up 1.5% YoY from $686.8M
- Q3 net loss $(5.6)M vs $1.3M income; loss per share $(0.07) vs $0.02
- Best category ostomy $53.3M, up 5.4%; worst wound care $48.0M, down 6.7%
- Cash $32.8M vs $27.6M; nine-month operating cash flow $(170.0)M vs $90.5M
- Outlook: commercial payor contracts representing $242M, or 12% of nine-month revenue, expected to transition through first-half 2026
Risk Factors
- New payor termination risk triggered by notice affecting agreements representing 12% of nine-month net revenue
- P&HS sale risk heightened by October 7 Purchase Agreement and obligation to reimburse Purchaser for first $65 million of separation costs
- CMS coverage risk from June 2025 NIPPV determination requiring stricter criteria for initial six-month COPD coverage
- Operational concentration risk following potential P&HS divestiture, leaving a smaller single-segment Patient Direct company
- Environmental litigation risk from ethylene oxide sterilization exposure at P&HS manufacturing facilities
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ACCENDRA HEALTH INC/VA/ quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.